Erratum to “A combined deficiency of tissue factor and PAR-4 is associated with fatal pulmonary hemorrhage in mice”
[Thromb. Res. 146 (2016) 46–50]
Michael F. Bode a, Nigel Mackman b,*
a University of North Carolina, Division of Cardiology, Department of Medicine, 160 Dental Circle, CB #7075, 6025 Burnett-Womack-Bldg., Chapel Hill, NC 27514-7075, USA
b University of North Carolina, Division of Hematology and Oncology, Department of Medicine, McAllister Heart Institute, 111 Mason Farm Road, 2312C Medical Biomolecular Research Bldg., CB #7126, Chapel Hill, NC 27599-7126, USA
The publisher regrets that Table 1 was presented incorrectly in the above published paper. The Table should have been presented as follows:
Table 1.
Expected and observed numbers of mice surviving to wean. Low-TF status is associated with a ~20% lethality on this C57BL/6J background27, which is also observed in our study when comparing the observed/expected survival ratio of all mTF−/− mice to all mTF+/+ mice. Chi-square test did not show any additional effect of PAR-4 status on survival in any of the groups. hTF+ indicates that at least one allele of human TF is present (hTF+/− or hTF+/+).
| Breeding pair | Genotype |
Expected |
Observed |
Observed |
Obs/E |
||
|---|---|---|---|---|---|---|---|
| mTF | hTF | PAR-4 | % | % | # | % | |
| mTF+/−, hTF+/−, PAR-4+/− × mTF+/−, hTF+/−, PAR-4+/− (breeding 1) | −/− | + | −/− | 6 | 4 | 3 | 70 |
| −/− | + | +/− | 13 | 12 | 8 | 93 | |
| −/− | + | +/+ | 6 | 3 | 2 | 46 | |
| +/− | + | −/− | 13 | 12 | 8 | 93 | |
| +/− | + | +/− | 25 | 38 | 26 | 151 | |
| +/− | + | +/+ | 13 | 9 | 6 | 70 | |
| +/+ | + | −/− | 6 | 4 | 3 | 70 | |
| +/+ | + | +/− | 13 | 13 | 9 | 104 | |
| +/+ | + | +/+ | 6 | 6 | 4 | 93 | |
| mTF−/−, hTF+/−, PAR-4+/− × mTF+/−, hTF+/−, PAR-4+/− (breeding 2) | −/− | + | −/− | 13 | 10 | 4 | 82 |
| −/− | + | +/− | 25 | 28 | 11 | 113 | |
| −/− | + | +/+ | 13 | 3 | 1 | 21 | |
| +/− | + | −/− | 13 | 21 | 8 | 164 | |
| +/− | + | +/− | 25 | 26 | 10 | 103 | |
| +/− | + | +/+ | 13 | 13 | 5 | 103 | |
The publisher would like to apologise for any inconvenience caused.
* Corresponding author at: Division of Hematology and Oncology, Department of Medicine, 111 Mason FarmRoad, 2312C Medical Biomolecular Research Bldg., CB #7126, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
E-mail addresses: michael_bode@med.unc.edu (M.F. Bode), nigel_mackman@med.unc.edu, nmackman@med.unc.edu (N. Mackman).